Global disparities in access to hepatitis C medicines before and during the early phase of the COVID-19 pandemic: an ARIMA-based interrupted time series analysis
Our study showed uneven access to DAAs globally, with higher prevalence-adjusted utilisation in high-income countries compared with lower-income countries. Our study also found that the COVID-19 pandemic has significantly decreased DAA sales in many countries. To counter these trends, additional strategies, such as price reductions, increased competition among manufacturers and licensing agreements, may help to improve access and utilisation of DAAs globally.
Authors
- Katie J. Suda
- Bethany Hedt‐Gauthier (ORCID: https://orcid.org/0000-0002-9689-5413)
- Marie Paul Nisingizwe (ORCID: https://orcid.org/0000-0003-2702-5841)
- Mina Tadrous (ORCID: https://orcid.org/0000-0003-1911-6129)
- Michael R. Law (ORCID: https://orcid.org/0000-0002-5637-6053)
- Nick Bansback (ORCID: https://orcid.org/0000-0002-1510-3462)
- Naveed Zafar Janjua (ORCID: https://orcid.org/0000-0001-5681-719X)
Institutions
- Harvard University (US)
- University of British Columbia (CA)
- University of Pittsburgh (US)
- University of Toronto (CA)
- Women's College Hospital (CA)
- BC Centre for Disease Control (CA)
- VA Pittsburgh Healthcare System (US)
- Harvard Global Health Institute (US)
Publication Details
- Journal
- BMJ Public Health
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1136/bmjph-2024-001340
- Citations
- 2
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 2.64
Funders
- Canadian Institutes of Health Research